What is the clinical significance of 5-oxoproline (pyroglutamic acid) in high anion gap metabolic acidosis following paracetamol (acetaminophen) exposure?

Clinical Toxicology

Volumn 51, Issue 9, 2013, Pages 817-827

  Liss, D B ^a   Paden, M S ^a   Schwarz, E S ^a   Mullins, M E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 oxoproline; Metabolic; Paracetamol; Pyroglutamic acid

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; AMINOTRANSFERASE; BICARBONATE; FLUCLOXACILLIN; GLUTATHIONE SYNTHASE; PARACETAMOL; PYROGLUTAMIC ACID;

ABDOMINAL PAIN; BACKACHE; BLOOD LEVEL; CLINICAL FEATURE; DEVELOPED COUNTRY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HIGH ANION GAP METABOLIC ACIDOSIS; HUMAN; METABOLIC ACIDOSIS; MORTALITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SYMPTOMATOLOGY; URINE LEVEL; WOUND INFECTION;

ACETAMINOPHEN; ACETYLCYSTEINE; ACIDOSIS; AMINO ACID METABOLISM, INBORN ERRORS; ANALGESICS, NON-NARCOTIC; ANTIPYRETICS; DISEASE SUSCEPTIBILITY; FREE RADICAL SCAVENGERS; GLUTATHIONE SYNTHASE; HUMANS; PYRROLIDONECARBOXYLIC ACID; SEVERITY OF ILLNESS INDEX;

EID: 84886630718     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2013.844822     Document Type: Review

References (48)

1. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. Annual Report of the American Association of Poison Control Centers National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol 2012; 50: 911-1164.
2. Khan LR, Oniscu GC, Powell JJ. Long-Term outcome following liver transplantation for paracetamol overdose. Transpl Int 2010 ; 23: 524-529.
3. Wiegand TJ, Wax PM, Schwartz T, Finkelstein Y, Gorodetsky R, Brent J; Toxicology Investigators Consortium Case Registry Investigators. The Toxicology Investigators Consortium Case Registry-The 2011 Experience. J Med Toxicol 2012; 8: 360-377.
4. James LP, Chiew A, Abdel-Rahman SM, Letzig L, Graudins A, Day P, Roberts D. Acetaminophen protein adduct formation following low-dose acetaminophen exposure: Comparison of immediaterelease vs extended-release formulations. Eur J Clin Pharmacol 2013 ; 69: 851-857.
5. Duewall JL, Fenves AZ, Richey DS, Tran LD, Emmett M. 5-oxoproline (pyroglutamic) acidosis associated with chronic acetaminophen use. Proc (Bayl Univ Med Cent) 2010; 23: 19-20.
6. C roal B L, G len A C, K elly C J, L ogan R W. T ransient 5-oxoprolinuria (pyroglutamic aciduria) with systemic acidosis in an adult receiving antibiotic therapy. Clin Chem 1998; 44: 336-340.
7. T ailor P, R aman T, G arganta C L, N jalsson R, C arlsson K, R istoff E, Carey HB. Recurrent HAGMA secondary to 5-oxoproline (pyroglutamic acid). Am J Kidney Dis 2005; 46: E4-10.
8. Rolleman EJ, Hoorn EJ, Didden P, Zietse R. Guilty as charged: Unmeasured urinary anions in a case of pyroglutamic acidosis. Neth J Med 2008; 66: 351-353.
9. Bonham JR, Rattenbury JM, Meeks A, Pollitt RJ. Pyroglutamic aciduria from vigabatrin. Lancet 1989; 1: 1452-1453.
10. Roth B, Woo O, Blanc P. Early metabolic acidosis and coma after acetaminophen ingestion. Ann Emerg Med 1999; 33: 452-456.
11. Gray TA, Buckley BM, Vale JA. Hyperlactataemia and metabolic acidosis following paracetamol overdose. Q J Med 1987; 65 : 811-821.
12. Green TJ, Bijlsma JJ, Sweet DD. Profound metabolic acidosis from pyroglutamic acidemia: An underappreciated cause of HAGMA. CJEM 2010; 12: 449-452.
13. R eddi A S, K unadi A R. R ecurrent anion gap metabolic acidosis in a woman with vertebral disc disease. Am J Emerg Med 2011; 29: 962.
14. Y ale S H, M azza J J. A nion gap acidosis associated with acetaminophen. Ann Intern Med 2000; 133: 752-753.
15. Hodgman MJ, Horn JF, Stork CM, Marraffa JM, Holland MG, Cantor R, Carmel PM. Profound metabolic acidosis and oxoprolinuria in an adult. Med Toxicol 2007; 3: 119-124.
16. Howie S, Tarn A, Soper C. A not so simple analgesic. NDT Plus 2010 ; 3: 573-575.
17. Zand L, Muriithi A, Nelsen E, Franco PM, Greene EL, Qian Q, El-Zoghby ZM. Severe anion gap metabolic acidosis from acetaminophen use secondary to 5-oxoproline (pyroglutamic acid) accumulation. Am J Med Sci 2012; 344: 501-504.
18. Humphreys BD, Forman JP, Zandi-Nejad K, Bazari H, Seifter J, Magee CC. Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. Am J Kidney Dis 2005; 46: 143-146.
19. R omero J E, H tyte N. A n unusual cause of high anion gap metabolic acidosis: Pyroglutamic acidemia. A case report. Am J Ther 2011.
20. M yall K, S idney J, M arsh A. M ind the gap! An unusual metabolic acidosis. Lancet 2011; 377: 526.
21. O Brien LM, Hooper M, Flemmer M, Marik PE. Chronic acetaminophen ingestion resulting in severe anion gap metabolic acidosis secondary to 5-oxoproline accumulation: An under diagnosed phenomenon. BMJ Case Rep 2012; 2012.
22. Foot CL, Fraser JF, Mullany DV. Pyroglutamic acidosis in a renal transplant patient. Nephrol Dial Transplant 2005; 20: 2836-2838.
23. P rasad, S. A case of high anion gap metabolic acidosis: What' s the anion? (abstract) Crit Care Med 2012; 40: 298.
24. Creer MH, Lau BW, Jones JD, Chan KM. Pyroglutamic acidemia in an adult patient. Clin Chem 1989; 35: 684-686.
25. Fenves AZ, Kirkpatrick HM III, Patel VV, Sweetman L, Emmett M. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): A role for acetaminophen. Clin J Am Soc Nephrol 2006; 1: 441-447.
26. Dempsey GA, Lyall HJ, Corke CF, Scheinkestel CD. Pyroglutamic acidemia: A cause of high anion gap metabolic acidosis. Crit Care Med 2000; 28: 1803-1807.
27. Leung PSC, Tsui SH, Siu TS, Tam S. Acquired 5-oxoprolinuria (Pyroglutamic acidaemia) as a cause of early high anion gap metabolic acidosis in acute massive paracetamol overdose. Hong Kong JEmerg Med 2011; 18: 264-270.
28. Alados Arboledas FJ, de la Olivia Senovilla P, Garcia Mu ñ oz MJ, Alonso Melgar A, Ruza Tarrío F. Acidosis piroglutámica asociada a paracetamol. An Pediatr (Barc) 2007; 67: 582-584.
29. P itt J J, H auser S. T ransient 5-oxoprolinuria and high anion gap metabolic acidosis: Clinical and biochemical fi ndings in eleven subjects. Clin Chem 1998; 44: 1497-1503.
30. Pitt JJ, Brown GK, Clift V, Christodoulou J. Atypical pyroglutamic aciduria: Possible role of paracetamol. J Inherit Metab Dis 1990 ; 13: 755-756.
31. Peter JV, Rogers N, Murty S, Gerace R, Mackay R, Peake SL. An unusual cause of severe metabolic acidosis. Med J Aust 2006; 185: 223-225.
32. Armenian P, Gerona RR, Blanc PD, Wu AH, Mookherjee S. 5-oxoprolinemia causing elevated anion gap metabolic acidosis in the setting of acetaminophen use. J Emerg Med 2012; 43: 54-57.
33. Kortmann W, van Agtmael MA, van Diessen J, Kanen BL, Jakobs C, Nanayakkara PW. 5-Oxoproline as a cause of high anion gap metabolic acidosis: An uncommon cause with common risk factors. Neth J Med 2008; 66: 354-357.
34. M ilosevic S, T ran K, O B rien B. A rare cause of high anion gap metabolic acidosis. Intern Med J 2013; 43: 100-101.
35. Chestnutt J, Heyburn G, Roberts B. Pyroglutamic aciduria: A cause of high anion-gap metabolic acidosis associated with common drugs. Ir Med J 2011; 104: 312-313.
36. R istoff E, L arsson A. P atients with genetic defects in the gammaglutamyl cycle. Chem Biol Interact 1998; 111-112: 113-121.
37. Mistry D, Stockley RA. Gamma-glutamyl transferase: The silent partner? COPD 2010; 7: 285-290.
38. Almaghlouth IA, Mohamed JY, Al-Amoudi M, Al-Ahaidib L, Al-Odaib A, Alkuraya FS. 5-Oxoprolinase defi ciency: Report of the fi rst human OPLAH mutation. Clin Genet 2012; 82: 193-196.
39. Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2007; 2: 16.
40. Amer H, Dockery F, Barrett N, George M, Witek K, Stanton J, Back D. Refractory metabolic acidosis in patients with sepsis following hemiarthroplasty for femoral neck fracture: A causative role for paracetamol and fl ucloxacillin? BMJ Case Rep 2011 ; pii: Bcr0520114292.
41. Brooker G, Jeffery J, Nataraj T, Sair M, Ayling R. High anion gap metabolic acidosis secondary to pyroglutamic aciduria (5-oxoprolinuria): Association with prescription drugs and malnutrition. Ann Clin Biochem 2007; 44: 406-409.
42. Holman M, ter Maaten JC. [Severe metabolic acidosis as a result of 5-oxoproline in acetaminophen use]. Ned Tijdschr Geneeskd 2010; 154: A1838. [Article in Dutch]
43. Lawrence DT, Bechtel LK, Charlton NP, Holstege CP. 5-oxoprolineinduced anion gap metabolic acidosis after an acute acetaminophen overdose. J Am Osteopath Assoc 2010; 110: 545-551.
44. Verma R, Polsani KR, Wilt J, Loehrke ME. 5-Oxoprolinuria as a cause of high anion gap metabolic acidosis. Br J Clin Pharmacol 2012 ; 73: 489-491.
45. Zein JG, Wallace DJ, Kinasewitz G, Toubia N, Kakoulas C. Early anion gap metabolic acidosis in acetaminophen overdose. Am J Emerg Med 2010; 28: 798-802.
46. Tokatli A, Kalkano ǧ lu-Sivri HS, Y ü ce A, Co ş kun T. Acetaminophen induced hepatotoxicity in a glutathione synthetase-defi cient patient. Turk J Pediatr 2007; 49: 75-76.
47. Nj å lsson R, Ristoff E, Carlsson K, Winkler A, Larsson A, Norgren S. Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase defi ciency. Hum Genet 2005 ; 116: 384-389.
48. Sathiyathasan S, Jeyanthan K, Hamid R. Metabolic acidosis in late pregnancy due to 5-oxoproline (pyroglutamic acid) - A case report. Open J Obstetr Gynecol 2012; 2: 170-173.